Compare Medpace Holdings Inc (MEDP) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Visa Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Visa Inc trades at $385.39 (market cap $704.20B). The key difference: Visa Inc is far larger — about 41.9× Medpace Holdings Inc's market cap, and Visa Inc pays a 0.71% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Visa Inc for 115 Days on average.
| MEDP | V | |
|---|---|---|
Market Cap | $16.82B | $704.20B |
Volume | 223,093 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $630.19 | $384.14 |
52-Week Low | $393.42 | $295.52 |
Typical Hold Time | 14 Days | 115 Days |
Enterprise Value | $16.44B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Visa (V) trades at $383.79, up 3.14% today, showing strong momentum near its 52-week high. The stock maintains bullish technical signals with consistent earnings beats and robust fundamentals, including 50.78% net margins and 61.79% ROE. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa at the forefront of payment innovation while maintaining dominant market positioning.
Visa presents a compelling investment case with strong analyst support (85% buy ratings) and a $422.24 price target offering 10% upside. However, elevated valuation multiples (P/E 31.92) and emerging fintech competition require monitoring. The company's consistent execution and AI integration provide growth catalysts, though regulatory scrutiny and payment disruption risks remain considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
